RxDoctor Payments Data

Sarah Ingalsbe-Geno

Physician Assistant · Rochester, NYNPI 1942290184

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 50 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • Phathom Pharmaceuticals, Inc.$188
  • Bayer$147
  • Lilly USA, LLC$131
  • Amgen$108
  • GSK$75
  • plus $397 from 14 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$10,252
Medicare patients
83
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$77,416
EliquisApixaban231$71,266
XareltoRivaroxaban42$12,462
Lagevrio (Eua)Molnupiravir13$12,071
GemtesaVibegron31$7,355
JardianceEmpagliflozin25$7,276
Tresiba Flextouch U-100Insulin Degludec15$6,350
Levothyroxine Sodium224$4,418
AlogliptinAlogliptin Benzoate23$2,228
Metoprolol Succinate111$2,205
EntrestoSacubitril/Valsartan11$2,014
Pantoprazole Sodium89$1,804
Torsemide140$1,670
Atorvastatin Calcium144$1,623
Methenamine Hippurate24$1,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$71,266231 claims
MerckLagevrio (Eua)$16$12,07113 claims
Boehringer IngelheimJardiance$26$7,27625 claims
NovartisEntresto$18$2,01411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →